

6. LITERATURVERZEICHNIS

1. Adamek HE, Weitz M, Breer H, Jakobs R, Schilling D, Riemann JF: Value of magnetic-resonance cholangio-pancreatography (MRCP) after unsuccessful endoscopic-retrograde cholangio-pancreatography (ERCP). *Endoscopy* 1997;29:741-744
2. Adams S, Baum RP, Adams M, Wenisch HC, Schumm-Draeger PM, Encke A, Usadel KH, Hör G: Zur klinischen Wertigkeit der Somatostatinrezeptorzintigraphie-Untersuchung zur prä- und intraoperativen Lokalisation von GEP-Tumoren. *Med Klin* 1997;92:138-143
3. Adler G, Beglinger C, Manns MP, Müller-Lissner S, Schmiegel W: *Klinische Gastroenterologie und Stoffwechsel*. Springer Verlag 2000:756-790
4. Albrecht T, Hoffmann C W, Wolf K J: Sonographie von Lebermetastasen mit leberspezifischem Kontrastmittel. *Radiologe* 2001;41:8-15
5. Angeli E, Vanzulli A, Gastrucci M, Venturini M, Sironi S, Zerbi A, Di Carlo V, Pozza G, Del Maschio A: Value of abdominal sonography and MR imaging at 0,5 T in preoperative detection of pancreatic insulinoma: a comparison with dynamic CT and angiography. *Abdom. Imaging* 1997;22: 295-303
6. Appleton GV, Bathurst NC, Virjee J, Cooper MJ, Williamson RC: The value of angiography in the surgical management of pancreatic disease. *Ann R Coll Surg Engl.* 1989 Mar;71(2):92-6.
7. Arnold R, Frank M, Kajdan U: Management of Gastroenteropancreatic Endocrine Tumors: The place of Somatostatin Analogues. *Digestion* 1994;55(suppl 3):107-113
8. Bader TR, Smelka RC, Chiu VC, Armao DM, Woosley JT: MRI of Carcinoid Tumors: Spectrum of Appearances in the Gastrointestinal Tract and Liver. *Journal of Magnetic Resonance Imaging* 2001;14:261-269
9. Bares R, Klever P, Hambuechen U: Positronemissionstomography with fluorine-18-labelled deoxyglucose (FDG) for the detection of pancreatic cancer: comparison with CT, ultrasonography and ERCP. *J Nucl Med* 1993;34:98-108
10. Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, Bombardieri E: Update on the treatment of neuroendocrine tumors. *Expert Rev Anticancer Ther.* 2003 Oct;3(5):631-642
11. Berber E, Flesher N, Siperstein A: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. *World J Surg* 2002;26:985-990
12. Bhutani M S, Hoffman B J, Velsa A, Hawes R H: Contrast-Enhanced Endoscopic Ultrasonography with Galactose Microparticles: SHU508 A (Levovist). *Endoscopy* 1997;29:635-639
13. Botella C, Valero G, Lahera Vargas M, Arechaga S, de Juan A, Varela Da Costa C, Sancho J: Diagnostic localization of insulinoma and prognostic value of postoperative glycemia monitoring. *Med Clin (Barc)* 2002;118:201-204
14. Bottger TC, Weber W, Beyer J, Junginger T: Value of tumor localization in patients with insulinoma. *World J Surg* 1990;14:107-114
15. Brambs HJ, Claussen CD: Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnet resonance imaging and angiography. *Endoscopy* 1993;25:58-68
16. Braun B, Günther, Schwerk: Pankreas. In: *Ultraschalldiagnostik*. ecomed Verlag, 1-114,

1998

17. Charles A, Proye G: Endocrine tumours of the pancreas: an update. *Aust N Z J Surg* 1998;68:90-100
18. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeilland J, Monetti N, Bombardieri E: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. *Eur J Nucl Med* 1998;25:1396-1403
19. Cannon ME, Carpenter SL, Elta GH, Nostrant TT, Kochmann ML, Ginsberg GG, Stotland B, Rosato EF, Morris JB, Eckhauser F, Scheiman JM: EUS compared with CT, magnetic resonance imaging and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms. *Gastrointest Endosc* 1999;50:27-33
20. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G: Revised Classification of Neuroendocrine Tumors of the Lung, Pancreas and Gut. *Digestion* 1994;55(suppl 3):11-23
21. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumours. *Lancet* 1998;352:799-805
22. Cassidy MA: Abdominal carcinomatosis, with probable adrenal involvement. *Proc. R. Soc. Med.* 1930;24:138-141
23. Clouse ME, Perry L, Stuart K, Stokes KR: Hepatic Arterial Chemoembolization for Metastatic Neuroendocrine Tumors. *Digestion* 1994;55(suppl 3):92-97
24. Creutzfeldt W: Historical Background and Natural History of Carcinoids. *Digestion* 1994;55(suppl 3):3-10
25. Cwikla JB, Buscombe JR, Mielcarek WA, Caplin ME, Watkinson AJ, Hilson AJ: Comparison of functional imaging and standard CT in evaluation of disease extent in patients with tumours showing neuroendocrine features. *Nucl Med Rev Cent East Eur.* 2001;4(1):27-34
26. Dähnert W: *Radiology Review Manual, Fourth Edition.* Williams & Wilkins Baltimore, 1999
27. Delorme S: Evaluating tumor vascularization with Doppler ultrasound. *Radiologe.* 1998 May;38(5):335-43.
28. Delorme S, Knoop MV: Non-invasive vascular imaging: assessing tumour vascularity. *Eur Radiol.* 1998;8(4):517-27.
29. Dietrich C F, Becker D: Signalverstärkte Sonographie verbessert Nachweis von Leber-raumforderungen. *Deutsches Ärzteblatt, Jg.99, Heft 24, Juni 2002, C1317-C1321*
30. Donowitz M et al.: Evaluation of patients with chronic diarrhea. *N Engl J Med* 1995;332:725-729
31. Doppman JL, Jensen RT: Localization of gastroenteropancreatic tumours by angiography. *Italian Journal of Gastroenterology and Hepatology* 1999 Oct;31(suppl 2):S163-166
32. Ectors N: Pancreatic endocrine tumors: diagnostic pitfalls. *Hepatogastroenterology.* 1999 Mar-Apr;46(26):679-90
33. Erriksson B, Öberg K, Stridsberg M: Tumor Markers in Neuroendocrine Tumors. *Digestion* 2000;62: 33-38
34. Erspamer V, Asero B: Identification of enteramine, the specific hormone of the

- enterochromaffin cell system as 5-hydroxytryptamine. *Nature* 1952;169:800-801.
35. Feyrter: Über diffuse endocrine epitheliale Organe. Barth Leipzig, 1938
 36. Frankton S, Bloom SR: Glucagonomas. *Baillere's Clinical Gastroenterology* 1996;10:697-705
 37. Friesen SR: Update on the diagnosis and treatment of rare neuroendocrine tumors. *Surg Clin N Amer* 1987;67:379-393
 38. Frilling A, Rogiers X, Knöfel WT, Broelsch CE: Liver Transplantation for Metastatic Carcinoid Tumors. *Digestion* 1994;55(suppl 3):104-106
 39. Gabril F, Jemsem RT: Pancreatic endocrine tumors: recent insights. *Clin Perspect Gastroenterol* 2001;4:19-29
 40. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME: Atabulated summary of the FDG PET literature. *J Nucl Med.* 2001 May;42(5 Suppl):1S-93S.
 41. Ganim RB, Norton JA: Recent advances in carcinoid pathogenesis, diagnosis and management. *Surg Oncol* 2000;9:173-179
 42. Gilligan et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. *American Journal of Gastroenterology* 1995;90: 32-542
 43. Gotthardt M, Dirkmorfeld LM, Wied MU, Rinke A, Behe MP, Schlieff A, Hoffken H, Alfke H, Joseph K, Klose KJ, Behr TM, Arnold R: Influence of Somatostatin Receptor Scintigraphy and CT/MRI on the Clinical Management of Patients with Gastrointestinal Neuroendocrine Tumors: An Analysis in 188 Patients. *Digestion.* 2003;68:80-85
 44. Grant CS: Insulinoma: Gastrointestinal endocrine Tumours. *Baillere's Clinical Gastroenterology* 1996 ;
 45. Gregor M: Therapeutic Principles in the Management of Metastasising Carcinoid Tumors: Drugs for Symptomatic Treatment. *Digestion* 1994;55(suppl 3):60-63
 46. Gross M, Engelhardt D, Höfler H, Janetschek P, Petrides PE, Ritter M, Schusdziarra V, Stier A, Vogelsang H: Neuroendokrine Tumoren des Gastrointestinaltraktes. *Manual Gastrointestinale Tumoren by Tumorzentrum München* 2001;203-214
 47. Gualdi GF, Casciani E, Polettoni: Imaging of neuroendocrine tumors. *Clin Ter.* 2001 Mar-Apr;152(2):107-121
 48. Hamilton SR, Aaltonen LA: World Health Organisation Classification of Tumours-Pathology and Genetics of Tumours of the Digestive System. Lyon, 2000
 49. Hellmann P, Ladjevardi S, Skkogseid B: Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. *World J Surg* 2002;26:1052-1056
 50. Hintze RE, Adler A, Veltzke H, Abou-Rebyeh H, Hammerstingl R, Vogl T, Felix R: Clinical significance of magnetic resonance cholangiopancreatography (MRCP) compared to endoscopic retrograde cholangiopancreatography (ERCP). *Endoscopy* 1997;29:182-187
 51. Higashi T, Tamaki N, Torizuka T: Differentiation of malignant from benign tumors by FDG PET: comparison with CT, US and endoscopic ultrasonography. *J Nucl Med* 1995;36:224-232
 52. Hohmann J, Skrok J, Puls R, Albrecht T: Charakterisierung fokaler Leberläsionen mit kontrastmittelgestütztem „low MI realtime“ Ultraschall und SonoVue. *Rofo Fortschr Geb*

- Röntgenstr N 2003;835-843
53. Höring E, Gaisberg v U, : Neuroendokrine Tumoren des Pankreas und Gastrointestinaltraktes. DMW 1991, 116. Jg., Nr. 31/32; 1197-1202
 54. Hopt UT, Heydasch U: Surgical relevance of diagnostic imaging of abdominal tumors- decision making in pancreatic tumor. Chirurg. 1997 Apr;68(4):325-33
 55. Huban RH, Adsay NV, Albores-Saavedra J, Compton C, Garret ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, Luttges J, Offerhaus GJ: Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-586
 56. Ichikawa T, Peterson MS, Federle MP, Baron RL, Haradome H, Kawamori Y, Nawano S, Araki T. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology.2000 Jul;216(1):163-71.
 57. Ihse I, Persson B, Tibblin S: Neuroendocrine Metastases of the Liver. World J. Surgery 1995;19:76-82,
 58. Imdahl A, Nitzsche E, Krautmann F, Högerle S, Boos S, Einert A, Sontheimer J, Farthmann EH: Evaluation of positronemissiontomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194-199
 59. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC, NakanoH, Wolf P: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2001 Jun;25(6):689-92.
 60. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K: [111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours:the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 1994 Dec;131(6):577-81.
 61. Jensen RT: Gastrinoma. Baillere´s Clinical Gastroenterology 1996;10: 603-643
 62. Jirasek T, Mandys V: Carcinoids of gastrointestinal tract: importance of determining differentiation and proliferation markers. Cesk Patol. 2003 Apr;39(2):47-53
 63. Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus C, Trautmann ME, Schwerk WB, Arnold R: Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dtsch. Med. Wschr.117(1992), 1025-1028
 64. Kaltsas G, Besser G M, Grossman A B: The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocrine Reviews 2004;25(3):458-511
 65. Kaneko K, Honda H, Hayashi T, Fukuya T, Ro T, Irie H, Masuda K: Helical CT evaluation of arterial invasion in pancreatic tumors: Comparison with angiography. Abdom Imaging 1997;22:204-207
 66. Klöppel G, Perren A, Heitz PU: Vom Karzinoid zum neuroendokrinen Tumor , Klassifizierung im Magen- Darm- Trakt und Pankreas. Dtsch Ärztebl 2003;100:A1932-1942 (Heft 28-29)
 67. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M Reubi JC: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731
 68. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJB, Dop FJ, de Herder WW, Reubi JC,

- Lamberts SWJ: Somatostatin Receptor Scintigraphy in Carcinoids, Gastrinomas and Cushing's Syndrom. *Digestion* 1994;55(suppl 3):54-59
69. Kulke MH, Mayer RJ : Carcinoid tumors. *N Engl J Med* 1999;340:858-868
70. Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL: Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. *Abdominal Imaging* 2004 May 27;29(3)
71. Lambeck F: 5-hydroxytryptamine in a carcinoid tumor. *Nature* 1953;172:910-911
72. Lamberts SW, Hofland LJ, Nobels FR: Neuroendocrine tumor markers. *Front Neuroendocrinol* 2001;22:309-339
73. Leen E, Angerson W J, Yarmenitis S, Bongartz G, Blomley, Del Maschio A, Sommaria V, Maresca G, Pezzoli C, Llull J B: Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. *European Journal of Radiology* 2002;41:200-206
74. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier D, Bonnin A: Pancreatic tumors: comparison of dual- phase helical CT and endoscopic sonography. *AJR Am J Roentgenol* 1998;170:1315-1322
75. McEntee GP, Nagorney DM, Kvols LK: Cytoreductive hepatic surgery for neuroendocrine tumors. *Surgery* 1990;108:1091
76. Mc Stay MK, Caplin ME: Carcinoid tumour. *Minerva Med* 2002;93:389-401
77. Meko JB, Doherty GM, Siegel BA, Norton JA: Evaluation of somatostatine-receptor scintigraphy for detecting neuroendocrine tumors. *Surgery* 1996;120:975-983
78. Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumors. *Cancer* 1997;79:813-829
79. Mössner J: Diagnose und Differentialdiagnose des Pankreaskarzinoms. *Praxis* 1997;86:397-400
80. Nawroth und Ziegler: *Klinische Endokrinologie und Stoffwechsel*. Springer Verlag 2001;S. 547-571
81. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW: Chromogranin A as a serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. *J Clin Endocrinol Metab* 1997;82:2622-2628
82. Nold R, Frank M, Kajdan U, Trost U, Klose KJ, Arnold R: Kombinierte Behandlung metastasierter endokriner Tumoren des Gastrointestinaltraktes mit Octreotid und Interferon-Alpha. *Z. Gastroenterol* 1994;32: 193-197
83. Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K: Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. *J Clin Endocrinol Metab* 1986;63:605-612
84. Norton JA et al.: Surgery to cure the Zollinger Ellison syndrome. *N Engl J Med* 1999;341:635-644
85. Norton JA: Surgical Management of Carcinoid Tumors: Role of Debulking and Surgery for Patients with Advanced Disease. *Digestion* 1994;55(suppl 3):98-103
86. Oberndorfer S: Karzinoide Tumoren des Dünndarms. *Frankfurter Z Pathol* 1907;1:426

87. Öberg K, Eriksson B, Tiensuu Janson E: Interferons Alone or in Combination with Chemotherapy or Other Biologicals in the Treatment of Neuroendocrine Gut and Pancreatic Tumors. *Digestion* 1994;55(suppl 3):64-69
88. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, Ellison EC, O'Dorisio MS: Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). *Semin Nucl Med.* 1995 Jul;25(3):251-61.
89. Owen NJ, Sohaib SA, Peppercorn PD, Monson JP, Grossman AB, Besser GM, Reznick RH. MRI of pancreatic neuroendocrine tumours. *Br J Radiol.* 2001 Oct;74(886):968-73.
90. Pape UF, Bomig M, Behrendt U, Tiling N, Wiedenmann B, Plockinger U: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. *Annals New York Academ of Sciences* 2004, April;1014:222-233
91. Park SK et al.: Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. *Baillere's Clinical Gastroenterology* 1996;10:673-696
92. Pearse AGE: The cytochemistry and ultrastructure of polypeptide hormone producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concepts. *J Histochem Cytochem* 1969;17:303-313
93. Pitre J, Soubrane O, Palazzo L, Chapuis Y: Endoscopic ultrasonography for the preoperativ localisation of insulinomas. *Pancreas* 1996;13:55-60
94. Plöckinger U, Wiedenmann B: Neuroendokrine Tumoren des Gastrointestinaltraktes. *Z Gatsroenterol* 2004;42:517-526
95. Quaia E, Bertolotto M, Calderan L, Mosconi E, Macelli RP: US characterization of focal hepatic lesions with intermitten high-acoustic-power mode and contrast material. *Academica Radiologica* 2003 Jul;10(7):739-50
96. Quaia E, Degobbis F, Tona G, Mosconi E, Bertolotto M, Pozzi M: Differential patterns of contrast enhancement in different focal liver lesions after injection of microbubble US contrast agent SonoVue. *Radiol Med (Torino).* 2004 Mar;107(3):155-65
97. Rajput A, Stellato TA, Faulhaber PF, Vesselle HJ, Miraldi F: The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. *Surgery.* 1998 Oct;124(4):793-8
98. Remmele W: *Pathologie* 1999, Band 2, Springer Verlag Berlin, ISBN 3-540-601198
99. Reubi JC, Kvols L, Krenning EP, Lamberts SWJ: Distribution of somatostatinreceptor in normal and tumor tissue. *Metabolism* 1990;30 (suppl 2):78-81
100. Ricke J, Hänninen E L, Amthauer H, Lemke A, Felix R: Assessment of the Vascularisation of Neuroendocrine Tumors by Stimulated Acoustic Emission of SH U 508A Ultrasound Contrast Agent and Color or Power Doppler Sonography. *Investigative Radiology* 2000, Volume 35, Number 4, 253-259
101. Rickes S, Ocran KW, Gerstenhauer G, Neye H, Wermke W: Evaluation of diagnostic criteria for liver metastases of adenocarcinomas and neuroendocrine tumours at conventional ultrasound, unenhanced power Doppler sonography and echo-enhanced ultrasound. *Dig Dis.* 2004;22(1):81-6.
102. Rickes S, Malferteiner P: Echo-enhanced sonography- an increasingly used procedure for the differentiation of pancreatic tumors. *Dig Dis.* 2004;22(1):32-8.

103. Rickes S, Unkrodt K, Ocran K, Neye H, Lochs H, Wermke W: Evaluation of doppler ultrasonography criteria for the differential diagnosis of pancreatic tumors. *Ultraschall Med.* 2000 Dec;21(6):253-8.
104. Rickes S, Unkrodt K, Ocran K, Neye H, Lochs H, Wermke W: Differential diagnosis of frequent pancreatic tumours with echo-enhanced power-Doppler sonography-presentation of case reports. *Z Gastroenterol.* 2002 Apr;40(4):235-40.
105. Rickes S, Unkrodt K, Ocran K, Neye H, Wermke W: Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echo-enhanced power-Doppler sonography. *Scand J Gastroenterol.* 2002 Nov;37(11):1313-20.
106. Rickes S, Unkrodt K, Ocran K, Neye H, Wermke W: Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy. *Pancreas.* 2003 Jan;26(1):76-81.
107. Rickes S, Malfertheiner P: Echo-enhanced ultrasound-anwe imaging modality for differentiation of pancreatic lesions. *Int J Colorectal Dis.* 2005 Jun 7;[Epub ahead of print]
108. Riker A, Libutti SK, Bartlett DL: Advances in the early detection, diagnosis and staging of pancreatic cancer. *Surg Oncol* 1997;6:157-169
109. Rindi et al.:ECL cell tumors and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. *Gastroenterology* 1999;116:532-542
110. Rösch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schudziarra V, Classen M: Staging of pancreatic and ampullary carcinoma by endoscopic ultrasound. *Gastroenterology* 1992;102:188-199
111. Rösch T, Lightdale CJ, Botet JF, Boyce GA, Sivak M VJr, Yasuada K, Heyder N, Palazzo L, Dancygier H, Schudziarra V: Localisation of pancreatic endocrine tumours by endoscopic ultrasonography. *N Engl J Med* 1992;326: 1721-1726
112. Rothmund M, Kisker O: Surgical Treatment of Carcinoid Tumors of the Small Bowel, Appendix, Colon and Rectum. *Digestion* 1994;55(suppl 3):86-91
113. Scherubl H, Bader M, Fett U, Hamm B, Schmidt-gayk H, Koppenhagen K, Dop FJ, Riecken EO, Wiedenmann B. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. *Gastroenterology.* 1993 Dec;105(6):1705-9.
114. Schmitt-Graff A, Nitschke R, Wiedenmann B:Gastroenteropancreatic neuroendocrine/endocrine tumors. Current pathologic-diagnostic view. *Pathologe.* 2001 Mar;22(2):105-13.
115. Schürmann G: Neuroendocrine tumors of the gastroenteropancreatic system. Diagnosis and surgical treatment. *Dtsch Med Wochenschr* 2000 Apr 14;125(15):461-4
116. Semelka RC, Ascher SM. MR imaging of the pancreas. *Radiology.*1993 Sept;188(3):593-602.
117. Seregini E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. *Annali of Oncology* 2001;12(suppl2):69-72
118. Service FJ et al.:Functioning insulinoma-incidence, recurrence and long term survival of patients: a 60 year study. *Mayo Clin Proc* 1991;66:711-719
119. Shets S, Hruban RK, Fishman EK: Helical CT of islet cell tumors of the pancreas: typical and atypical manifestations. *AJR* 2002;179:725-730

120. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Grothers JG, Mellrath EM: Localization of neuroendocrine tumors with [In] DTPA-octreotidescintigraphy (Octreoscan): a comparative study with CT nad Mrimaging. *Q J M* 1998;91:295-301
121. Siperstein AE, Berber E: Cryablation, percutaneous alcohol injection and radiofrequency ablation for treatment of neuroendocrine liver metastases. *World J Surg* 2001 ;25 :693-696
122. Soto JA, Barish MA, Yucel EK, Siegenberg D, Ferrucci JT, Chuttani R: Magnetic resonance cholangiography: with comparison with endoscopic retrograde cholangiopancreatography. *Gastroenterol* 1996;110:589-597
123. Stafford-Johnson DB, Francis IR, Eckhauser FE, Knol JA, Chang AE: Dual-phase helical CT of non functional islet cell tumors. *J Comput Assist Tomogr* 1998;22:335-339
124. Stiefelhagen P: Gastrointestinale neuroendokrine Tumoren: symptomatische und zytoreduktive Therapieoptionen in fortgeschrittenen Stadien. *Arzneimitteltherapie*, 23. Jahrgang, Heft 4, 2005; 142-143
125. Sugiyama M, Atomi Y, Hachiya J: Intraductal paillary tumours of the pancreas. Evaluation with magnetic resonance cholangiopancreatography. *Am J Gastroenterol* 1998;93:156-159
126. Sundin A, Eriksson B, Bergström M, Langström B, Öberg K, Örlfors H : PET in the Diagnosis of Neuroendocrine Tumors. *Ann. N.Y. Acad. Sci.* 2004;1014:246-257
127. Teichmann R, Becker R, Dilger J, Jakober B, Lamberts R, Pereira PH L, Tiling-Grosse S: Multiple endokrine Neoplasien (MEN). *Interdisziplinäres Tumorzentrum Tübingen* 1997; 29-49
128. Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB: Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. *Radiology* 2000;214:483-490
129. Thomas L: Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, hrsg. von Lothar Thomas. 6. Aufl., Frankfurt/Main : TH-Books-Verlags-Gesellschaft, 2005, S.644-646
130. Tiensuu Janson EM, Oberg KE: Carcinoid tumors. *Baillieres Clinical Gastroenterology* 1996 Dec;10(4):589-601
131. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R, Gullo L: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. *Eur J Gastroenterol Hepatol* 2001; 13:55-58
132. Ueno N, Tomiyama T, Tano S, Wada S, Aizawa T, Kimura K: Utility of endoscopic ultrasonography with color doppler function for the diagnosis of islet cell tumor. *Am J Gastroenterol* 1996;91:772-776
133. Valdes Olmos RA, Hoefnagel CA, Bais E, Boot H, Taal B, de Kraker J, Vote PA: Therapeutic advances of nuclear medicine in oncology. *Rev Esp Med Nucl* 2001;20:547-557
134. Valkema R, Steens J, Cleton FJ, Pauwels EK: The diagnostic utility of somatostatinreceptor scintigraphy in oncology. *J Cancer Res Oncol* 1996;122:513-532
135. Van Der Hoef M, Crook DW, Marincek B, Weishaupt D: Primary neuroendocrine tumors of the liver: MRI features in two cases. *Abdominal Imaging* 2003 Oct 28
136. Van Eijck CHJ, de Jong M, Breemann W AP, Slooter GD, Marquet RL, Krenning EP: Somatostainreceptor imaging and therapy of pancreatic endocrine tumors. *Ann Oncol* 1999

(Suppl 4);10:177-181

137. Van Hoe L, Gryspeerdt S, Marchal G, Baert AL, Mertens L: Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. *AJR Am J Roentgenol* 1995;165:1437-1439
138. Vick C, Zech C J, Höpfner S, Waggershauser T, Reiser M: Bildgebung bei neuroendokrinen Tumoren des Pankreas. *Der Radiologe*, Band 43, Heft 4, April 2003, 293-300
139. Vinik AI, McLeod MK, Fig LM, Shapiro B, Lloyd RV, Cho K: Clinical features, diagnosis and localization of carcinoid tumors and their management. *Gastroenterol Clin North Am* 1989;18:865-896
140. Wermers RA et al. : The glucagonoma syndrome. Clinical and pathological features in 21 patients. *Medicine (Baltimore)* 1996;75:53-63
141. Wermke Wolfram, Gaßmann Bernhard: Tumordiagnostik der Leber mit Echosignalverstärkern –Farbatlas, Berlin 1998, Springer Verlag
142. Wermke Wolfram: Sonographische Differenzialdiagnose Leberkrankheiten-Lehrbuch und systematischer Atlas, Deutscher Ärzteverlag, Köln 2006
143. Wilder RM, Allen FN, Power MH, Robertson HZE: Carcinoma of islands of pancreas, hyperinsulinism and hypoglycemia. *JAMA*,1927;89:348-355
144. Williams ED, Sander M: Classification of carcinoid tumours. *Lancet* 1963; I: 238-239
145. Zimmer T, Stölzel U, Bäder, Koppenhagen K, Hamm B, Buhr H, Riecken EO, Wiedenmann B: Endoscopic ultrasonography and somatostatinreceptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. *Gut* 1996;39:562-568
146. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U: Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. *Eur J Nucl Med*. 1997 Jun;24(6):678-82